Cancer Biopsy Market size was over USD 23.5 billion in 2024 and is anticipated to reach USD 63.9 billion by the end of 2037, expanding at a CAGR of 8.7% during the forecast period, i.e., 2025-2037. In 2025, the industry size of cancer biopsy is estimated at USD 25.5 billion. Key drivers include increasing demand for minimally invasive procedures, the development of liquid biopsies, and the integration of molecular diagnostics that enable personalized treatment plans. Factors such as growing awareness of early cancer detection and supportive government initiatives for cancer screening are further fueling the market expansion.
For instance, as per the U.S. Embassy and Consulates, in September 2024, the U.S. Australia, India, and Japan announced the launch of the Quad Cancer Moonshot to strengthen the overall cancer care ecosystem in the Indo-Pacific. It aims to improve health infrastructure, expand research collaborations, build data systems, and provide greater support for the prevention, detection, treatment, and post-treatment care of cancer. As per the National Cancer Institute, new cancer cases per year are projected to reach 29.9 million, leading to 15.3 million cancer-related deaths, worldwide. Owing to these rising cases and advancements in therapies, the global cancer biopsy market is projected to witness a significant rise during the forecast period.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
8.7% |
|
Base Year Market Size (2024) |
USD 23.5 billion |
|
Forecast Year Market Size (2037) |
USD 63.9 billion |
|
Regional Scope |
|
Cancer Type (Breast, Colorectal, Stomach, Lung, Liver, Prostrate, Ovarian, And Other Cancer Types)
In cancer type, the breast cancer segment in the cancer biopsy market is projected to register the highest share of 21.1% by the end of 2037. According to the American Cancer Society, 310,720 new cases of invasive breast cancer are projected to be diagnosed in women in 2024, causing as many as 42,250 deaths, among women. It further predicts that nearly 2,790 men will also be diagnosed with breast cancer by the end of 2024, registering approximately 530 deaths from the disease. Owing to the rising amount of breast cancers especially among women, the segment is anticipated to garner the highest growth rate in the upcoming years, in the cancer biopsy market.
End user (Hospitals, Cancer Research Centers, Diagnostic Centers, and Research and Academics)
Hospitals are projected to dominate the end user segment primarily due to their comprehensive healthcare services and advanced diagnostic capabilities. The hospitals are equipped with state-of-the-art imaging and laboratory facilities, facilitating a wide range of biopsy procedures, including surgical and minimally invasive techniques. The increasing number of cancer cases and the need for timely diagnosis and treatment further strengthen hospital’s positions as primary providers of biopsy services. As healthcare continues to evolve, hospitals are likely to remain at the forefront of the cancer biopsy market.
Our in-depth analysis of the cancer biopsy market includes the following segments:
|
Biopsy Type |
|
|
Products & Services |
|
|
Cancer Type |
|
|
End user |
|
APAC Market Statistics
As per a report published in June 2023, by the National Library of Medicine, with more than 60% of the world's total population residing in the region, one-half of all cancer cases and 58% of cancer deaths, occur in Asia Pacific. Cervical cancer remains to be one of the most commonly diagnosed cancers worldwide even though it is highly preventable. It is referred to as a disease of inequity with a very low screening coverage of 4% in the Western Pacific and 18% in Southeast Asia, which is far below the WHO recommendation of 70% screening coverage of eligible women. These factors are projected to boost the Asia Pacific cancer biopsy market growth during the forecast period.
Increasing government cancer screening initiatives, growth of private healthcare facilities with advanced diagnostic technologies, and rising medical tourism are some of the driving factors for the India cancer biopsy market. In February 2024, Continental Hospitals announced the launch of the Early Detection Liquid Biopsy Test. The test provides capabilities of early detection, personalized care recommendations, and hands-on health management strategies based on a person’s genetic profile.
China cancer biopsy market is expanding significantly driven by the rising prevalence of multiple cancer types and a growing emphasis on early detection. As per the National Library of Medicine article published in March 2022, there were over 4 million cancer cases in China in 2022. These rising cases are expected to boost the cancer biopsy market in China during the forecast period. Additionally, China’s burgeoning biotech sector is accelerating the development of innovative biopsy techniques, catering to the demand for personalized cancer therapies.
North America Market Analysis
North America cancer biopsy market is boosted by the presence of prominent players in the region. These players engage in several competitive strategies to meet the rising demand for advanced therapies. In June 2023, Quest Diagnostics announced the completion of the Haystack Oncology acquisition. Quest aims to incorporate Haystack’s MRD technology into the development of new blood-based clinical lab services for solid tumor cancers. Market activities such as these are projected to further drive the industry’s growth significantly in the region.
As per an article by the National Cancer Institute, an estimated of over 2 million new cases of cancer will be diagnosed in the United States, causing nearly 611,720 deaths from the disease, in U.S. Companies headquartered in the country are also participating in several acquisitions and collaborations, to maintain competition in the market. For instance, Agilent Technologies, Inc. announced the acquisition of Resolution Bioscience, aiming to expand Agilant’s capabilities in NGS-based cancer diagnostics and serve the fast-growing precision medicine market requirements.
According to an article by the Canadian Cancer Society, cancer-related deaths are expected to rise from 86,700 in 2023 to 88,100 in 2024 in Canada. The rising cancer cases, growing demand for personalized medicines, and advanced healthcare system are boosting the cancer biopsy market growth in the country. Furthermore, significant investments in R&D activities in the country are also promoting various developments in terms of advanced treatment therapies. Strong governmental support is another factor boosting the industry’s growth.
Companies are adopting a wide range of strategies to remain competitive in the market. This includes development and innovations, majorly in tissue biopsies, liquid biopsies, and advanced molecular diagnostics. For instance, in September 2023, Mermaid Medical launched M∙Biopsy semi-automatic and fully automatic biopsy needles, for soft tissue biopsy solutions. Collaborations and partnerships with research institutions, diagnostic labs, and pharmaceutical companies are also common, allowing firms to expand their technological capabilities. Regulatory approvals are also explored strategically by these prominent players for obtaining certifications and meeting global standards.
Some of the prominent players in the market include:
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?